{"id":58632,"date":"2026-03-12T06:59:59","date_gmt":"2026-03-12T05:59:59","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/current-role-of-atg-in-gvhd-prevention-optimizing-post-transplantation-outcomes-through-combination-with-ptcy\/"},"modified":"2026-03-12T06:59:59","modified_gmt":"2026-03-12T05:59:59","slug":"current-role-of-atg-in-gvhd-prevention-optimizing-post-transplantation-outcomes-through-combination-with-ptcy","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/current-role-of-atg-in-gvhd-prevention-optimizing-post-transplantation-outcomes-through-combination-with-ptcy\/","title":{"rendered":"Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2026 Mar 10;100:102749. doi: 10.1016\/j.coi.2026.102749. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Graft versus host disease (GVHD) is one of the major complications of allogeneic hematopoietic cell transplantation (allo-HCT), contributing significantly to post-transplant morbidity and mortality. Anti-thymocyte globulin (ATG) is a widely used GVHD prophylaxis in combination with a calcineurin inhibitor and an antimetabolite. Post-transplant cyclophosphamide (PTCy) has been a milestone in haploidentical transplantation, and its use has expanded to allo-HCT performed from matched related and unrelated donors with notable success. In this review, we discuss how post-transplantation outcomes can be optimized through a combination of ATG with PTCY. We summarize the biological rationale, current clinical evidence, and remaining uncertainties regarding this dual in vivo T-cell depletion strategy, highlighting its potential to enhance GVHD control, reduce immunosuppressive burden, and improve survival across different donor settings.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812347\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20260312015947&amp;v=2.19.0.post6+133c1fe\">41812347<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2026.102749\">10.1016\/j.coi.2026.102749<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2026 Mar 10;100:102749. doi: 10.1016\/j.coi.2026.102749. Online ahead of print. ABSTRACT Graft versus host disease (GVHD) is one of the major complications of allogeneic hematopoietic cell transplantation (allo-HCT), contributing significantly to post-transplant morbidity and mortality. Anti-thymocyte globulin (ATG) is a widely used GVHD prophylaxis in combination with a calcineurin inhibitor and an antimetabolite. &#8230; <a title=\"Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/current-role-of-atg-in-gvhd-prevention-optimizing-post-transplantation-outcomes-through-combination-with-ptcy\/\" aria-label=\"Read more about Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-58632","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/58632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=58632"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/58632\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=58632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=58632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=58632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}